<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39403609</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-7074</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>International journal of general medicine</Title><ISOAbbreviation>Int J Gen Med</ISOAbbreviation></Journal><ArticleTitle>Dynamic Characteristics of Lymphocyte Subsets and Their Predictive Value for Disease Progression and Prognosis in Primary Infection and Unvaccinated COVID-19 Patients.</ArticleTitle><Pagination><StartPage>4559</StartPage><EndPage>4577</EndPage><MedlinePgn>4559-4577</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/IJGM.S478912</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="UNASSIGNED">Our cohort study aimed to investigate the dynamic changes of lymphocyte subsets and their abilities to predict disease severity and prognosis in primary infection and unvaccinated COVID-19 patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A total of 773 cases, including 718 primary infection and unvaccinated COVID-19 patients and 55 controls. COVID-19 patients were assigned to severe and nonsevere groups according to disease severity, as well as survival and death groups according to prognosis. Serum samples were collected to measure the numbers of total lymphocytes and lymphocyte subsets. The differences among different severity groups were analyzed. Spearman correlation was performed to assess associations between lymphocyte subsets and disease severity and prognosis. Meanwhile, receiver operating characteristic (ROC) curves were also analyzed to find optimal cutoff points.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">At admission, the severe group demonstrated significantly lower total lymphocyte counts and percentages, CD3<sup>+</sup> and CD3<sup>+</sup>CD4<sup>+</sup> T cell counts and percentages, CD3<sup>+</sup>CD8<sup>+</sup> T cell counts, CD19<sup>+</sup> B cell counts and CD56<sup>+</sup> NK cell counts and percentages than the nonsevere group. Meanwhile, compared with the survival group, the death group also had lower total lymphocyte counts and percentages, CD3<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> T cell counts. Additionally, differences in these parameters were also noticed within four weeks after admission. Furthermore, Spearman analysis reported that disease severity was negatively correlated with lymphocyte counts and percentages, CD3<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> T cell counts, CD3<sup>+</sup> and CD3<sup>+</sup>CD4<sup>+</sup> T cell percentages (<i>r</i>=-0.166, -0.179, -0.173, -0.186, -0.127, -0.117, -0.149, respectively)(all <i>P</i>&lt;0.05). The prognosis of death was also negatively correlated with total lymphocyte counts and percentages, CD3<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> T cell counts (<i>r</i>=-0.125, -0.121, -0.123, -0.123, -0.091, respectively)(all <i>P</i>&lt;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In primary infection and unvaccinated COVID-19 patients total lymphocytes and T cell, B cell and NK cell subsets at COVID-19 onset play valuable roles in predicting disease severity and prognosis.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRY" NlmCategory="UNASSIGNED">Chinese Clinical Trial Register ChiCTR2000034563.</AbstractText><CopyrightInformation>© 2024 Zhang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Xinyi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The First Ward of Internal Medicine, Public Health Clinical Centre of Chengdu, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology &amp; Metabolism, Sichuan University West China Hospital, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Zhu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Drug Clinical Trial Center, Public Health Clinical Centre of Chengdu, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Department, Public Health Clinical Centre of Chengdu, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Legal Services Division, Public Health Clinical Centre of Chengdu, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Bennan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The First Ward of Internal Medicine, Public Health Clinical Centre of Chengdu, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The First Ward of Internal Medicine, Public Health Clinical Centre of Chengdu, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dafeng</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6792-641X</Identifier><AffiliationInfo><Affiliation>The First Ward of Internal Medicine, Public Health Clinical Centre of Chengdu, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Int J Gen Med</MedlineTA><NlmUniqueID>101515487</NlmUniqueID><ISSNLinking>1178-7074</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">lymphocyte subsets</Keyword><Keyword MajorTopicYN="N">prediction</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">severity</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>4</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39403609</ArticleId><ArticleId IdType="pmc">PMC11472736</ArticleId><ArticleId IdType="doi">10.2147/IJGM.S478912</ArticleId><ArticleId IdType="pii">478912</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu G, Gao GF, Tan W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the Mystery and the Miracle. J Med Virol. 2020;92(4):401–402. doi:10.1002/jmv.25678</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25678</ArticleId><ArticleId IdType="pmc">PMC7166628</ArticleId><ArticleId IdType="pubmed">31950516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji W, Wang W, Zhao X, et al. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020;92(4):433–440. doi:10.1002/jmv.25682</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25682</ArticleId><ArticleId IdType="pmc">PMC7138088</ArticleId><ArticleId IdType="pubmed">31967321</ArticleId></ArticleIdList></Reference><Reference><Citation>Gates B. Responding to COVID-19- A once-in-a-century pandemic? N Engl J Med. 2020;382(18):1677–1679. doi:10.1056/NEJMp2003762</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2003762</ArticleId><ArticleId IdType="pubmed">32109012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269. doi:10.1038/s41586-020-2008-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. COVID-19 weekly Epidemiological Update. Geneva: World Health Organization; 2023.</Citation></Reference><Reference><Citation>Attaway AH, Scheraga RG, Bhimraj A, Biehl M, Hatipoğlu U. Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ. 2021;372:n436. doi:10.1136/bmj.n436</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n436</ArticleId><ArticleId IdType="pubmed">33692022</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Commission of the People’s Republic of China. The seventh trial version of the novel coronavirus pneumonia diagnosis and treatment guidance. Available from: http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml. Accessed October
08, 2024.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical characteristics of 138hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of 2019 Novel Coronavirus Infection in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson N, Kvalsvig A, Barnard LT, et al. Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality. Emerg Infect Dis. 2020;26(6):1339–1441. doi:10.3201/eid2606.200320</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2606.200320</ArticleId><ArticleId IdType="pmc">PMC7258483</ArticleId><ArticleId IdType="pubmed">32168463</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida-Pititto B, Dualib PM, Zajdenverg L, et al.; Brazilian Diabetes Society Study Group (SBD). Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. DiabetolMetabSyndr. 2020;12:75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456786</ArticleId><ArticleId IdType="pubmed">32874207</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. doi:10.1093/cid/ciaa248</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa248</ArticleId><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Lan L, Luo D, et al. Lymphocyte subsets with the lowest decline at baseline and the slow lowest rise during recovery inCOVID-19 critical illness patients with diabetes mellitus. Diabet Res Clin Pract. 2020;167:108341. doi:10.1016/j.diabres.2020.108341</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2020.108341</ArticleId><ArticleId IdType="pmc">PMC7373679</ArticleId><ArticleId IdType="pubmed">32707212</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Wang Y, Zhao B, et al. Overall reduced lymphocyte especially T and B subsets closely related to the poor prognosis and the disease severity in severe patients with COVID-19 and diabetes mellitus. Diabetol Metab Syndr. 2021;13(1):5. doi:10.1186/s13098-020-00622-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13098-020-00622-3</ArticleId><ArticleId IdType="pmc">PMC7802992</ArticleId><ArticleId IdType="pubmed">33436069</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Zheng Y, Kang J, et al. Not only high number and specific comorbidities but additionally, age are closely related to progression and poor prognosis in patients with COVID-19. Front.Med;2022. 736109. doi:10.3389/fmed.2021.736109</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.736109</ArticleId><ArticleId IdType="pmc">PMC8782432</ArticleId><ArticleId IdType="pubmed">35071254</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Yuan X, Gao F, et al. High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients. Front Immunol. 2022;13:899930. doi:10.3389/fimmu.2022.899930</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.899930</ArticleId><ArticleId IdType="pmc">PMC9295452</ArticleId><ArticleId IdType="pubmed">35865540</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahallawi WH, Khabour OF, Zhang Q, et al. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17cytokine profile. Cytokine. 2018;104:8–13. doi:10.1016/j.cyto.2018.01.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2018.01.025</ArticleId><ArticleId IdType="pmc">PMC7129230</ArticleId><ArticleId IdType="pubmed">29414327</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Dai RS, Chen YZ, Zhuang YG. Prognostic significance of lymphocyte subpopulations for ICU-acquired infections in patients with sepsis: a retrospective study. J Hosp Infect. 2023;140:40–45. doi:10.1016/j.jhin.2023.05.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2023.05.022</ArticleId><ArticleId IdType="pubmed">37399906</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh Motahar Vahedi H, Bagheri A, Jahanshir A, Seyedhosseini J, Vahidi E. Association of lymphopenia with short term outcomes of sepsis patients; a brief report. Arch Acad Emerg Med. 2019;7(1):e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377227</ArticleId><ArticleId IdType="pubmed">30847449</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohlstein P, Gussen H, Bartneck M, et al. Prognostic relevance of altered lymphocyte subpopulations in critical illness and sepsis. J Clin Med. 2019;8(3):353. doi:10.3390/jcm8030353</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8030353</ArticleId><ArticleId IdType="pmc">PMC6463123</ArticleId><ArticleId IdType="pubmed">30871101</ArticleId></ArticleIdList></Reference><Reference><Citation>Luperto M, Zafrani L. T cell dysregulation in inflammatory diseases in ICU. Intensive Care Med Exp. 2022;10(1):43. doi:10.1186/s40635-022-00471-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40635-022-00471-6</ArticleId><ArticleId IdType="pmc">PMC9590394</ArticleId><ArticleId IdType="pubmed">36279072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Luo S, Qin R, et al. Long-term infection of SARS-CoV-2changed the body’s immune status. Clin Immunol. 2020;218:108524. doi:10.1016/j.clim.2020.108524</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108524</ArticleId><ArticleId IdType="pmc">PMC7351676</ArticleId><ArticleId IdType="pubmed">32659373</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Mao L, Yuan X, et al. Prediction model based on the combination of cytokines and lymphocyte subsets for prognosis ofSARS-CoV-2 infection. J Clin Immunol. 2020;40(7):960–969. doi:10.1007/s10875-020-00821-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-020-00821-7</ArticleId><ArticleId IdType="pmc">PMC7357264</ArticleId><ArticleId IdType="pubmed">32661797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Jiang D, Gao L, et al. Clinical characteristics and predictive value of lower CD4 + T-cell level in patients with moderate and severeCOVID-19: a multicenter retrospective study. BMC Infect Dis. 2021;21:57. doi:10.1186/s12879-020-05741-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05741-w</ArticleId><ArticleId IdType="pmc">PMC7803000</ArticleId><ArticleId IdType="pubmed">33435865</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Li L, Liu J, et al. The characteristics and predictive role of lymphocyte subsets in COVID-19 patients. Int J Infect Dis. 2020;99:92–99. doi:10.1016/j.ijid.2020.06.079</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.06.079</ArticleId><ArticleId IdType="pmc">PMC7398035</ArticleId><ArticleId IdType="pubmed">32758688</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei M, Marjani M, Mahmoudi S, Mortaz E, Mansouri D. Dynamic changes of lymphocyte subsets in the course of COVID-19. Int Arch Allergy Immunol. 2021;182(3):254–262. doi:10.1159/000514202</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000514202</ArticleId><ArticleId IdType="pmc">PMC7900469</ArticleId><ArticleId IdType="pubmed">33498051</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95–103. doi:10.1111/j.1365-2249.2004.02415.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2004.02415.x</ArticleId><ArticleId IdType="pmc">PMC1808997</ArticleId><ArticleId IdType="pubmed">15030519</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Gue W, et al. Clinical and immunological features in severe and moderate coronavirus disease. J Clin Investig. 2019;130:2620–2629. doi:10.1172/JCI137244</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020;92:1549–1555. doi:10.1002/jmv.25781</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25781</ArticleId><ArticleId IdType="pmc">PMC7228290</ArticleId><ArticleId IdType="pubmed">32196707</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi:10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia. AJR Am J Roentgenol. 2020;17:1–6. doi:10.2214/AJR.20.22961</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/AJR.20.22961</ArticleId><ArticleId IdType="pubmed">32181672</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. Emerg Microb Infect. 2020;9:727–732. doi:10.1080/22221751.2020.1746199</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1746199</ArticleId><ArticleId IdType="pmc">PMC7170333</ArticleId><ArticleId IdType="pubmed">32196410</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Chen Y, Lin R, Han K. Clinical feature of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020;80:e14–e18. doi:10.1016/j.jinf.2020.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.005</ArticleId><ArticleId IdType="pmc">PMC7102640</ArticleId><ArticleId IdType="pubmed">32171866</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupia T, Scabini S, Pinna SM, Di Perri G, De Rosa FG, Corcione S. 2019-novel coronavirus outbreak: a new challenge. J Glob Antimicr Res. 2020;21:22–27. doi:10.1016/j.gar.2020.02.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gar.2020.02.021</ArticleId><ArticleId IdType="pmc">PMC7102618</ArticleId><ArticleId IdType="pubmed">32156648</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa270</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa270</ArticleId><ArticleId IdType="pmc">PMC7184444</ArticleId><ArticleId IdType="pubmed">32173725</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Cai X, Wang H, et al. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clin. Chim. Acta. 2020;507:174–180. doi:10.1016/j.cca.2020.04.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.04.024</ArticleId><ArticleId IdType="pmc">PMC7194694</ArticleId><ArticleId IdType="pubmed">32339487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239. doi:10.1001/jama.2020.2648</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;86:388–393. doi:10.1016/j.jinf.2020.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.02.016</ArticleId><ArticleId IdType="pmc">PMC7102539</ArticleId><ArticleId IdType="pubmed">32112884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang MQ, Wang XH, Chen YL, et al. Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:215–218. doi:10.3760/cma.j.issn.1001-0939.2020.0013</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1001-0939.2020.0013</ArticleId><ArticleId IdType="pubmed">32164091</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng YD, Meng K, Guan HQ, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E004. doi:10.3760/cma.j.cn112148-20200220-00105</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112148-20200220-00105</ArticleId><ArticleId IdType="pubmed">32120458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan S, Yiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol. 2020;92:797–806. doi:10.1002/jmv.25783</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25783</ArticleId><ArticleId IdType="pmc">PMC7228368</ArticleId><ArticleId IdType="pubmed">32198776</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni M, Tian FB, Xiang DD, Yu B. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19. J Med Virol. 2020;92(11):2600–2606. doi:10.1002/jmv.26070</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26070</ArticleId><ArticleId IdType="pmc">PMC7283881</ArticleId><ArticleId IdType="pubmed">32470153</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimeno S, Ventura PS, Castellano JM, et al. Prognostic implications of neutrophil-lymphocyte ratio in COVID-19. Eur J Clin Invest. 2021;51(1):e13404. doi:10.1111/eci.13404</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13404</ArticleId><ArticleId IdType="pubmed">32918295</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci. 2022;23(7):3636. doi:10.3390/ijms23073636</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23073636</ArticleId><ArticleId IdType="pmc">PMC8998851</ArticleId><ArticleId IdType="pubmed">35408994</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus diseases 2019 (COVID-19). Front Immunol. 2020;11:827. doi:10.3389/fifimmu.2020.00827</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fifimmu.2020.00827</ArticleId><ArticleId IdType="pmc">PMC7205903</ArticleId><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B, Fan CY, Wang AI, et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China. J Infect. 2020;81:e51–e60. doi:10.1016/j.jinf.2020.04.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.04.012</ArticleId><ArticleId IdType="pmc">PMC7166040</ArticleId><ArticleId IdType="pubmed">32315725</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Guo W, Dong Y, et al. Elevated exhaustion levels of NK and CD8(+) T Cells as indicators for progression and prognosis of COVID-19 disease. Front Immunol. 2020;11:580237. doi:10.3389/fimmu.2020.580237</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.580237</ArticleId><ArticleId IdType="pmc">PMC7591707</ArticleId><ArticleId IdType="pubmed">33154753</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin R, He L, Yang Z, et al. Identification of parameters representative of immune dysfunction in patients with severe and fatal COVID-19 infection: a systematic review and meta-analysis. Clin Rev Allergy Immunol. 2023;64(1):33–65. doi:10.1007/s12016-021-08908-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08908-8</ArticleId><ArticleId IdType="pmc">PMC8763427</ArticleId><ArticleId IdType="pubmed">35040086</ArticleId></ArticleIdList></Reference><Reference><Citation>Krämer B, Knoll R, Bonaguro L, et al. Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. 2021;54(11):2650–69.e14. doi:10.1016/j.immuni.2021.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.09.002</ArticleId><ArticleId IdType="pmc">PMC8416549</ArticleId><ArticleId IdType="pubmed">34592166</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahern DJ, Ai Z, Ainsworth M. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell. 2022;185(5):916–38.e58. doi:10.1016/j.cell.2022.01.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.012</ArticleId><ArticleId IdType="pmc">PMC8776501</ArticleId><ArticleId IdType="pubmed">35216673</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesenak M, Brndiarova M, Urbancikova I, et al. Immune parameters and COVID-19 infection - associations with clinical severity and disease prognosis. Front Cell Infect Microbiol. 2020;10:364. doi:10.3389/fcimb.2020.00364</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00364</ArticleId><ArticleId IdType="pmc">PMC7338601</ArticleId><ArticleId IdType="pubmed">32695683</ArticleId></ArticleIdList></Reference><Reference><Citation>Brauning A, Rae M, Zhu G, et al. Aging of the immune system: focus on natural killer cells phenotype and functions. Cells. 2022;11(6):1017. doi:10.3390/cells11061017</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11061017</ArticleId><ArticleId IdType="pmc">PMC8947539</ArticleId><ArticleId IdType="pubmed">35326467</ArticleId></ArticleIdList></Reference><Reference><Citation>Großkopf A, Simm A. Alterung des Immunsystems [Aging of the immune system]. Z Gerontol Geriatr. 2022;55(7):553–557. doi:10.1007/s00391-022-02107-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00391-022-02107-6</ArticleId><ArticleId IdType="pmc">PMC9483890</ArticleId><ArticleId IdType="pubmed">36121472</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao B, Liu Q, Du Q, et al. Characteristics and differences in mpox patients with and without hiv infection: a retrospective cross-sectional study in Chengdu, China. Int J Gen Med. 2024;17:1381–1393. doi:10.2147/IJGM.S456198</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S456198</ArticleId><ArticleId IdType="pmc">PMC11011692</ArticleId><ArticleId IdType="pubmed">38617056</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>